Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.

David F. McDermott(Beth Israel Deaconess Medical Center), Michael B. Atkins(Georgetown University), Raluca Predoiu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rustem Gafanov(Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology), Sabina Signoretti(Brigham and Women's Hospital), Jahangeer Malik(Western General Hospital), Frede Donskov(Aarhus University Hospital), Charles Schloss(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jae‐Lyun Lee(Ulsan College), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alexandr Poprach(Masaryk University), James Larkin(Trinity College Dublin), Alexandra Snyder(MedStar Washington Hospital Center), Yiwei Zhang(Anhui University of Science and Technology), Scott S. Tykodi(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Qing Zhao(Sichuan University), Mark D. Kochenderfer(Carilion Roanoke Memorial Hospital)

Journal of Clinical Oncology

May 20, 2020

Cited by 14

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.9k

|Journal of Clinical Oncology|2009|4.6k

Related Papers